Anupam Rasayan India Ltd Q1 FY27 Results

Anupam Rasayan India Ltd has reported a robust financial performance for the quarter ending June 30, 2026 (Q1 FY27).

Total Revenue: Rs 6,675 million (Q1 FY26: Rs 4,907 million), a 36% year-on-year increase.
PAT: Rs 512 million (Q1 FY26: Rs 485 million), a 6% year-on-year increase.

Reader Takeaway: Strong revenue growth and a major long-term contract offset slower profit gains.

What just happened

The company announced its Q1 FY27 financial results, showcasing significant year-on-year growth in revenue and EBITDA. Revenue surged by 36% to Rs 6,675 million, while EBITDA grew by 35% to Rs 1,749 million. The EBITDA margin remained strong at 26.2%. Profit After Tax (PAT) saw a 6% increase, reaching Rs 512 million.

Why this matters

This performance indicates strong business momentum and effective strategy execution in specialty chemicals and contract development and manufacturing (CDMO). The revenue growth suggests increasing demand for its products and services.

The backstory

Anupam Rasayan operates in the specialty chemicals and CDMO space. The company focuses on complex chemistries, including fluorination and multi-step synthesis, serving diverse industries like agrochemicals, pharmaceuticals, and personal care.

What changes now

Key strategic developments signal future growth potential. Anupam Rasayan successfully commercialized Ethyl Trifluoroacetate (ETFA) using flow chemistry, a global first, enhancing its complex fluorination capabilities. Additionally, a Letter of Intent (LOI) was signed with BASQUEVOLT, S.A. for a specialty chemical supply contract, potentially worth US$300 million over ten years. The proposed acquisition of Bliss GVS Pharma is also moving forward with a definitive agreement signed.

Risks to watch

While revenue growth is strong, the PAT growth at 6% is notably lower. The successful integration of Bliss GVS Pharma and the realization of the BASQUEVOLT contract revenue will be crucial.

Peer comparison

(No peer comparison data available in the filing.)

Context metrics (time-bound)

• Total Revenue in Q1 FY27: Rs 6,675 million (up 36% YoY).
• EBITDA in Q1 FY27: Rs 1,749 million (up 35% YoY).
• PAT in Q1 FY27: Rs 512 million (up 6% YoY).
• EBITDA Margin: 26.2% in Q1 FY27.
• BASQUEVOLT LOI: Estimated US$300 million over 10 years.

What to track next

Investors will be keen to observe the progress of the Bliss GVS Pharma acquisition, the conversion of the BASQUEVOLT LOI into a firm order, and sustained revenue and profit growth in subsequent quarters.